Invokamet XR (Canagliflozin/Metformin HCl) Patent Expiration, LOE Window & CMS Spending

Invokamet XR (Canagliflozin/Metformin HCl) by Johnson & Johnson: FDA Orange Book core substance LOE 2029-08-26, 0 AB generics, $11.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN205879 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-08-26
Last Listed Patent or Exclusivity Date2029-08-26
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.3M
2024 Medicare Part D Spend$10.2M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.